Management challenges and therapeutic advances in congenital adrenal hyperplasia
Open accessThe DOI matches its Crossref record; 156 of the 157 references it cites were found in a registry or an index; 30 of the 174 sources its claims cite were checked for support.
Abstract
Treatment for congenital adrenal hyperplasia (CAH) was introduced in the 1950s following the discovery of the structure and function of adrenocortical hormones. Although major advances in molecular biology have delineated steroidogenic mechanisms and the genetics of CAH, management and treatment of this condition continue to present challenges. Management is complicated by a combination of comorbidities that arise from disease-related hormonal derangements and treatment-related adverse effects. The clinical outcomes of CAH can include life-threatening adrenal crises, altered growth and early puberty, and adverse effects on metabolic, cardiovascular, bone and reproductive health. Standard-of-care glucocorticoid formulations fall short of replicating the circadian rhythm of cortisol and controlling efficient adrenocorticotrophic hormone-driven adrenal androgen production. Adrenal-derived 11-oxygenated androgens have emerged as potential new biomarkers for CAH, as traditional biomarkers are subject to variability and are not adrenal-specific, contributing to management challenges. Multiple alternative treatment approaches are being developed with the aim of tailoring therapy for improved patient outcomes. This Review focuses on challenges and advances in the management and treatment of CAH due to 21-hydroxylase deficiency, the most common type of CAH. Furthermore, we examine new therapeutic developments, including treatments designed to replace cortisol in a physiological manner and adjunct agents intended to control excess androgens and thereby enable reductions in glucocorticoid doses. This Review focuses on challenges and advances in the management and treatment of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. New therapeutic developments are discussed, including novel glucocorticoid therapies, adjunct agents aimed at controlling excess androgens, and cell-based and gene-based therapies. Challenges in the management of congenital adrenal hyperplasia (CAH) arise from multiple hormonal imbalances, the intrinsic tendency of the CAH-affected adrenal gland to overproduce androgens and limited treatment options, which often necessitate glucocorticoid excess. The relationship between glucocorticoid and mineralocorticoid actions should be considered in the management of replacement therapies in CAH. Patients are at risk of life-threatening adrenal crises with hypoglycaemia, most often triggered by infectious illnesses and exacerbated by adrenaline deficiency. Traditional biomarkers vary with glucocorticoid dose or time of day and are not adrenal-specific, reflecting the need for new biomarkers; for example, the biologically active 11-oxygenated androgens, which are elevated in CAH. Circadian glucocorticoid replacement and adjunct non-glucocorticoid therapies promise to enable glucocorticoid dose reduction; furthermore, the development of personalized gene and cellular therapies is under way. Challenges in the management of congenital adrenal hyperplasia (CAH) arise from multiple hormonal imbalances, the intrinsic tendency of the CAH-affected adrenal gland to overproduce androgens and limited treatment options, which often necessitate glucocorticoid excess. The relationship between glucocorticoid and mineralocorticoid actions should be considered in the management of replacement therapies in CAH. Patients are at risk of life-threatening adrenal crises with hypoglycaemia, most often triggered by infectious illnesses and exacerbated by adrenaline deficiency. Traditional biomarkers vary with glucocorticoid dose or time of day and are not adrenal-specific, reflecting the need for new biomarkers; for example, the biologically active 11-oxygenated androgens, which are elevated in CAH. Circadian glucocorticoid replacement and adjunct non-glucocorticoid therapies promise to enable glucocorticoid dose reduction; furthermore, the development of personalized gene and cellular therapies is under way.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
24 Valid · 0 Not valid · 106 Not checked · 24 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Serum levels of 11-oxygenated androgens are higher in patients with 21-OHD CAH on replacement therapy when compared with age-matched and sex-matched control individuals20.”
§ Management challenges and therapeutic advances in congenital adrenal hyperplasia > Management challenges > Biochemical monitoring
What the sources say
- Supportedcites [20] Turcu, A. F. et al. Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in classic 21-hydroxylase deficiency. Eur. J. Endocrinol. 174, 601–609 (2016). source
The Results section 'Androgens and androgen precursors in sera of 21OHD patients' (p. Results) states that the four 11oxC19 steroids (11OHAD, 11KAD, 11OHT, 11KT) were significantly higher in 21OHD patients than controls (3- to 4-fold, p<0.0001), in both sexes, and the Abstract (Results) repeats this. The Subjects and Methods ('Human serum samples') supplies the two qualifiers the claim carries: patients were sampled 'while on their usual glucocorticoid replacement' and were compared with '38 age- and sex-matched controls'. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Unsurprisingly, inadequate hormonal control is common, and approximately one-third of patients in two large cohort studies of patients with classic CAH had normal serum levels of androstenedione, reflecting good hormonal control22,23.”
§ Management challenges and therapeutic advances in congenital adrenal hyperplasia > Currently available treatments > Glucocorticoid therapy
What the sources say
- Supportedcites [22] Arlt, W. et al. Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. J. Clin. Endocrinol. Metab. 95, 5110–5121 (2010). source
The Results (Serum steroid hormones) report normal androstenedione levels in 36% of patients in both the classic and nonclassic CAH groups. The Abstract describes normal androstenedione in only 36% and contrasts it with suppressed levels suggestive of overtreatment. This paper supports the finding for one of the two cohorts cited; it does not itself report results for both studies. (LLM, conf=0.92)
- Partly supportedcites [23] Finkielstain, G. P. et al. Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 97, 4429–4438 (2012). sourceExperimental — accuracy not yet measured
The Results (Adrenal hormones; page not provided) report that approximately 30% of classic CAH patients had acceptable hormonal control, but that figure is based on 17-OHP, not androstenedione. The same passage says about half of patients had elevated or suppressed androstenedione; it does not report that one-third of classic patients had normal androstenedione. This paper describes one cohort, not both cohorts cited in the sentence. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“All synthetic glucocorticoids have a narrow therapeutic index, and regimens or doses targeted to normalize or suppress 17-OHP in CAH can lead to over-replacement and associated metabolic comorbidities such as obesity and insulin resistance24.”
§ Management challenges and therapeutic advances in congenital adrenal hyperplasia > Management challenges > Biochemical monitoring
What the sources say
- Partly supportedcites [24] Speiser, P. W. et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 103, 4043–4088 (2018). sourceExperimental — accuracy not yet measured
The guideline’s Evidence sections state that attempts to completely normalize 17OHP typically cause overtreatment and that complete suppression indicates overtreatment. Another Evidence passage reports obesity and increased insulin-resistance measures among people with CAH, but it does not establish that 17OHP-targeted over-replacement causes those metabolic outcomes. Page numbers are unavailable in our copy. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients with CAH have increased cardiometabolic morbidity22,81.”
§ Management challenges and therapeutic advances in congenital adrenal hyperplasia > Management challenges > Cardiometabolic morbidity
What the sources say
- Supportedcites [22] Arlt, W. et al. Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. J. Clin. Endocrinol. Metab. 95, 5110–5121 (2010). source
The Discussion reports a high prevalence of obesity, hypercholesterolemia, and insulin resistance among the adults with CAH studied. It also reports higher diastolic blood pressure in women with classic CAH than in population controls. These findings support the attributed increase in cardiometabolic morbidity. (LLM, conf=0.92)
- Partly supportedcites [81] Subbarayan, A., Dattani, M. T., Peters, C. J. & Hindmarsh, P. C. Cardiovascular risk factors in children and adolescents with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin. Endocrinol. 80, 471–477 (2014). sourceExperimental — accuracy not yet measured
The Results (Hypertension; page unavailable) report significantly elevated systolic blood pressure in the studied children and adolescents with CAH, and the Discussion (page unavailable) reports obesity above the cited general-population figures. These findings support increased cardiometabolic risk factors in this cohort, but the paper does not establish increased cardiometabolic morbidity across patients with CAH generally. (LLM, conf=0.87)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A population-based Swedish study (n = 714 patients with CAH and 71,400 control individuals) found an increased risk of fragility fractures in patients with CAH91.”
§ Management challenges and therapeutic advances in congenital adrenal hyperplasia > Management challenges > Risk for low bone mineral density
What the sources say
- Supportedcites [91] Falhammar, H. et al. Increased prevalence of fractures in congenital adrenal hyperplasia: a Swedish population-based national cohort study. J. Clin. Endocrinol. Metab. 107, e475–e486 (2022). source
The Abstract (Design, Setting, and Participants) reports 714 patients with CAH and 71,400 matched controls from Swedish population-based registers. The Abstract (Results) reports significantly more major osteoporotic fractures in patients with CAH, supporting the citing sentence’s characterization of increased fragility-fracture risk. (LLM, conf=0.88)
plainstates an associationn = 714- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
83 more claims · 9 with their cited sources checked
Create a free account to see all 154 claims and to verify the 144 references still open.
- It may state two separate claims as one. 63
- Probably not a substantial claim. 7
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients with simple virilising CAH due to 21α-hydroxylase deficiency have 1–5% residual enzymatic activity, sufficient to prevent the salt-wasting crisis.”
From Congenital adrenal hyperplasia complicated by gonadotropin-dependent precocious puberty (2024) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Hydrocortisone is the preferred glucocorticoid in children with CAH owing to its short half-life and the fact that it has minimal impact on the growth plate.4”
From Congenital adrenal hyperplasia complicated by gonadotropin-dependent precocious puberty (2024) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Management challenges and therapeutic advances in congenital adrenal hyperplasia > Currently available treatments > Mineralocorticoid therapy
“n = 716, aged 3–18 years”
§ Management challenges and therapeutic advances in congenital adrenal hyperplasia > Currently available treatments > Mineralocorticoid therapy
“younger children (aged <18 months) than in adolescents (18.5% versus 4.9%)”
Citations
Cites
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
Self-citationLiu, D., Ahmet, A., Ward, L., Krishnamoorthy, P., Mandelcorn, E. D., Leigh, R., Brown, J. P., Cohen, A., & Kim, H. (2013) · Allergy, Asthma & Clinical Immunology · doi:10.1186/1710-1492-9-30 · Cited by 1,268
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Self-citationCongenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Self-citationHealth status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients
Arlt, W., Willis, D. S., Wild, S. H., Krone, N., Doherty, E. J., Hahner, S., Han, T. S., Carroll, P. V., Conway, G. S., Rees, D. A., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0917 · Cited by 506
Endocrine Regulation of the Growth Plate
Nilsson, O., Marino, R., De Luca, F., Phillip, M., & Baron, J. (2005) · Hormone Research in Paediatrics · doi:10.1159/000088791 · Cited by 441
Glucocorticoid-Induced Osteoporosis
Buckley, L., & Humphrey, M. B. (2018) · New England Journal of Medicine · doi:10.1056/nejmcp1800214 · Cited by 438
Hahner, S., Spinnler, C., Fassnacht, M., Burger-Stritt, S., Lang, K., Milovanovic, D., Beuschlein, F., Willenberg, H. S., Quinkler, M., & Allolio, B. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3191 · Cited by 394
Cited by
Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia
Auchus, R. J., Hamidi, O., Pivonello, R., Bancos, I., Russo, G., Witchel, S. F., Isidori, A. M., Rodien, P., Srirangalingam, U., Kiefer, F. W., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404656 · Cited by 79
Self-citationPhase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia
Sarafoglou, K., Kim, M. S., Lodish, M. B., Felner, E. I., Martinerie, L., Nokoff, N., Clemente, M., Fechner, P. Y., Vogiatzi, M. G., Speiser, P., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404655 · Cited by 62
Genetic control of typical and atypical sex development
Reyes, A. P., León, N. Y., Frost, E. R., & Harley, V. R. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00754-x · Cited by 63
Newfield, R. S., Sarafoglou, K., Fechner, P. Y., Nokoff, N., Auchus, R. J., Vogiatzi, M. G., Jeha, G. S., Giri, N., Roberts, E., Sturgeon, J., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad270 · Cited by 39
Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review
Topouzis, S., Papapetropoulos, A., Alexander, S. P. H., Cortese-Krott, M. M., Kendall, D. A., Martemyanov, K. A., Mauro, C., Nagercoil, N., Panettieri, R. A., Patel, H. H., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.17458 · Cited by 43
“The resultant adrenal stimulation diverts the accumulated steroid pre-cursors toward excessive synthesis of adrenal androgens (Mallappa & Merke, 2022).”
Metadata
- Authors
- Mallappa, A., & Merke, D. P.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Merke, Deborah P.
- Venue
- Nature Reviews Endocrinology
- Published
- 2022-04-11
- Volume
- 18
- Issue
- 6
- Pages
- 337-352
- ISSN
- 1759-5029 (ISSN-L)
- 1759-5037
- PMC
- PMC8999997
- OpenAlex
- W4223486597
- Semantic Scholar
- a5491bf3f75c42886c629c3217bc7b0c27f5e4ac
- Cited by
- 113
- References
- 157
- Citations by year
- 2026: 19 · 2025: 23 · 2024: 35 · 2023: 27 · 2022: 9
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Reviews Endocrinology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- congenital adrenal hyperplasia, 21-hydroxylase deficiency, glucocorticoid therapy, adrenal crisis, hyperandrogenism, 11-oxygenated androgens, biomarkers, diurnal cortisol rhythm, adrenal androgen production, steroid-sparing therapy, cell therapy, gene therapy, steroidogenesis, comorbidities
- MeSH terms
- Adrenal Hyperplasia, Congenital, Androgens, Glucocorticoids, Humans, Hydrocortisone, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Management challenges and therapeutic advances in congenital adrenal hyperplasia. https://app.cochat.ai/papers/10.1038/s41574-022-00655-w
- The paper
- Mallappa, A., & Merke, D. P. (2022). Management challenges and therapeutic advances in congenital adrenal hyperplasia. Nature Reviews Endocrinology. https://doi.org/10.1038/s41574-022-00655-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.